<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is a pressing need for new effective therapeutic strategies for addressing the epidemic of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Leptin has been shown to reduce <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and has recently been shown to normalize fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations in a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of polygenic <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Overall, these findings suggest that leptin may be an effective therapeutic option for both type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>However, short-term human clinical studies in overweight and <z:mp ids='MP_0001261'>obese</z:mp> patients with recently diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have reported minimal efficacy of leptin administration to lower blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>Herein, the role of leptin in the maintenance of <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis and the potential use of leptin in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are discussed </plain></SENT>
</text></document>